Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152061 · ClinicalTrials.gov registry record · NA
The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00152061: Completed NA study, sponsored by Stanford University.
NCT00152061 is a NA study that has completed, run by Stanford University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00152061, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
In this study the researchers will be enrolling patients who are failing their current antiretroviral regimen who also have resistance to 3TC or FTC. Patients will have their current antiretroviral regimen changed based on resistance testing and also be randomly assigned to either include, or not include 3TC/FTC in this new regimen. The purpose of the research is to investigate whether the change in therapy results in a decrease in the amount of virus particles and an increase in the CD4 cell count. In addition the researchers are investigating the relationship between the existence of resistance and the rate of decrease in viral load, and also to determine if continuing 3TC/FTC (despite being resistant to the medications) has any effect on the rate of decrease of viral load, or effect on CD4 counts.
Interventions
- DRUG 3TC and FTC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00152061
The ClinicalTrials.gov registry entry for NCT00152061 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3TC and FTC is the first listed.
NCT00152061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00152061 about?
NCT00152061 is a clinical study titled "The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens". In this study the researchers will be enrolling patients who are failing their current antiretroviral regimen who also have resistance to 3TC or FTC. Patients will have their current antiretroviral regimen changed based on resistance testing and also be randomly assigned to either include, or not in...
What is the current status of trial NCT00152061?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2005-01. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00152061?
The interventions under investigation include: 3TC and FTC (DRUG).
Who is sponsoring clinical trial NCT00152061?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.